You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America.

The TB:HIV Study writing Group
AIDS:
doi: 10.1097/QAD.0000000000001333
ORIGINAL ARTICLE: PDF Only
Abstract

Objectives: The high mortality among HIV/tuberculosis (TB) co-infected patients in Eastern Europe (EE) is partly explained by the high prevalence of drug-resistant TB. It remains unclear whether outcomes of HIV/TB patients with rifampicin/isoniazid-susceptible TB in EE differ from those in Western Europe (WE) or Latin America (LA).

Methods: One-year mortality of HIV-positive patients with rifampicin/isoniazid-susceptible TB in EE, WE and LA was analysed and compared in a prospective observational cohort study. Factors associated with death were analysed using Cox regression models

Results: 341 patients were included (EE 127, WE 165, LA 49). Proportions of patients with disseminated TB (50%, 58%, 59%) and initiating rifampicin + isoniazid + pyrazinamide-based treatment (93%, 94%, 94%) were similar in EE, WE and LA respectively, while receipt of antiretroviral therapy (ART) at baseline and after 12 months was lower in EE (17%, 39%, 39%, and 69%, 94%, 89%). The one-year probability of death was 16% (95%CI 11%-24%) in EE, vs. 4% (2%-9%) in WE and 9% (3%-21%) in LA; p < 0.0001. After adjustment for injecting drug use (IDU), CD4-cell count and receipt of ART, those residing in EE were at nearly 3-fold increased risk of death compared to those in WE/LA (aHR 2.79 (1.15-6.76); p = 0.023).

Conclusions: Despite comparable use of recommended anti-TB treatment, mortality of patients with rifampicin/isoniazid-susceptible tuberculosis remained higher in EE when compared with WE/LA. The high mortality in EE was only partially explained by IDU, use of ART and CD4 cell count. These results call for improvement of care for TB/HIV patients in EE.

Copyright (C) 2017 Wolters Kluwer Health, Inc.